Management und Diagnostik von Staphylococcus-aureus-Blutstrominfektionen

ZUSAMMENFASSUNG

Blutstrominfektionen durch Staphylococcus aureus sind schwere Infektionserkrankungen, die mit dem Risiko von sekundären Absiedlungen, Rekurrenzen und hohen Sterblichkeitsraten assoziiert sind. Bei adäquater Diagnostik und Therapie kann das Outcome wesentlich verbessert werden. Alle Patienten mit Staphylococcus-aureus-Bakteriämie sollten infektiologisch betreut werden, um die Einhaltung der Therapiestandards zu gewährleisten. Medikamente der Wahl sind Cefazolin und Flucloxacillin bei MSSA und Daptomycin (cave: nicht bei pulmonalem Fokus) und Vancomycin bei MRSA-Infektionen. Die Therapie sollte für mindestens 14 Tage intravenös erfolgen. Inwiefern eine Oralisierung bei Patienten mit unkomplizierten Bakteriämien erfolgen kann, ist derzeit Gegenstand von Studien. Erste Daten lassen drauf schließen.

• Literatur

• 1 Hagel S, Kaasch AJ, Weis S, Seifert H, Pletz MW, Rieg S. [Staphylococcus aureus Bacteraemia – an Interdisciplinary Challenge]. Anasthesiol Intensivmed Notfallmed Schmerzther 2019; 54: 206-216
• 2 Laupland KB, Lyytikainen O, Sogaard M. et al The changing epidemiology of Staphylococcus aureus bloodstream infection: a multinational population-based surveillance study. Clin Microbiol Infect 2013; 19: 465-471
• 3 Fätkenheuer G, Walger P, Fölsch U. Public Health: Infektiologische Expertise nötig. Dtsch Arztebl 2019; 116: A-734/B-604/C-596
• 4 Pletz MW, Weis S, Forstner C, Wagenlehner F. [Urosepsis]. Urologe A 2018; 57: 79-92
• 5 Lopez-Cortes LE, Del Toro MD, Galvez-Acebal J. et al Impact of an evidence-based bundle intervention in the quality-of-care management and outcome of Staphylococcus aureus bacteremia. Clin Infect Dis 2013; 57: 1225-1233
• 6 Vogel M, Schmitz RP, Hagel S, Pletz MW. et al Infectious disease consultation for Staphylococcus aureus bacteremia – A systematic review and meta-analysis. J Ubfect 2016; 72: 19-28
• 7 Kimmig A, Weis S, Hagel S, Forstner C, Kesselmeier M, Pletz MW. [Infectious Disease Consultations in Patients with Staphylococcus Aureus Bacteraemia – a Retrospective Observational Study at Jena University Hospital]. Dtsch Med Wochenschr 2018; 143: e2
• 8 Loubet P, Burdet C, Vindrios W. et al Cefazolin versus anti-staphylococcal penicillins for treatment of methicillin-susceptible Staphylococcus aureus bacteraemia: a narrative review. Clin Microbiol Infect 2018; 24: 125-132
• 9 Brook I. Inoculum effect. Rev Infect Dis 1989; 11: 361-368
• 10 Lee S, Kwon KT, Kim HI. et al Clinical implications of cefazolin inoculum effect and beta-lactamase type on methicillin-susceptible Staphylococcus aureus bacteremia. Microb Drug Resist 2014; 20: 568-574
• 11 Weis S, Kesselmeier M, Davis JS. et al Cefazolin versus anti-staphylococcal penicillins for the treatment of patients with Staphylococcus aureus bacteremia. Clin Microbiol Infect 2019; 25: 818-827
• 12 Paul M, Zemer-Wassercug N, Talker O. et al Are all beta-lactams similarly effective in the treatment of methicillin-sensitive Staphylococcus aureus bacteraemia?. Clin Microbiol Infect 2011; 17: 1581-1586
• 13 Beganovic M, Cusumano JA, Lopes V. et al Comparative Effectiveness of Exclusive Exposure to Nafcillin or Oxacillin, Cefazolin, Piperacillin/Tazobactam, and Fluoroquinolones Among a National Cohort of Veterans With Methicillin-Susceptible Staphylococcus aureus Bloodstream Infection. Open Forum Infect Dis 2019; 6: ofz270
• 14 Habib G, Lancellotti P, Antunes MJ. et al 2015 ESC Guidelines for the management of infective endocarditis: The Task Force for the Management of Infective Endocarditis of the European Society of Cardiology (ESC). Endorsed by: European Association for Cardio-Thoracic Surgery (EACTS), the European Association of Nuclear Medicine (EANM). Eur Heart J 2015; 36: 3075-3128
• 15 Liu C, Bayer A, Cosgrove SE. et al Clinical practice guidelines by the infectious diseases society of america for the treatment of methicillin-resistant Staphylococcus aureus infections in adults and children: executive summary. Clin Infect Dis 2011; 52: 285-292
• 16 Zent C, Smith P. Study of the effect of concomitant food on the bioavailability of rifampicin, isoniazid and pyrazinamide. Tuber Lung Dis 1995; 76: 109-113
• 17 Polasa K, Krishnaswamy K. Effect of food on bioavailability of rifampicin. J Clin Pharmacol 1983; 23: 433-437
• 18 Thwaites GE, Scarborough M, Szubert A. et al Adjunctive rifampicin for Staphylococcus aureus bacteraemia (ARREST): a multicentre, randomised, double-blind, placebo-controlled trial. Lancet 2018; 391: 668-678
• 19 Rieg S, Joost I, Weiss V. et al Combination antimicrobial therapy in patients with Staphylococcus aureus bacteraemia – a post hoc analysis in 964 prospectively evaluated patients. Clin Microbiol Infect 2017; 23: 406 e1-e8
• 20 Stein C, Makarewicz O, Forstner C, Weis S, Hagel S, Loffler B. et al Should daptomycin-rifampin combinations for MSSA/MRSA isolates be avoided because of antagonism?. Infection 2016; 44: 499-504
• 21 Falagas ME, Vouloumanou EK, Samonis G, Vardakas KZ. Fosfomycin. Clin Microbiol Rev 2016; 29: 321-347
• 22 Zasowski EJ, Trinh TD, Claeys KC. et al Multicenter Observational Study of Ceftaroline Fosamil for Methicillin-Resistant Staphylococcus aureus Bloodstream Infections. Antimicrob Agents Chemother 2017; 61 (02) e02015-16
• 23 Rieg S, Kern WV. Die nosokomiale Staphylococcus aureus-Bakteriämie. Krankenhaushygiene up2date 2011; 6: 261-274
• 24 Weis S, Kaasch AJ, Rieg S, Loffler B, Hagel S, Forstner C. et al Staphylococcus aureus bacteremia – a distinct entity. Dtsch Med Wochenschr 2015; 140: 982-989
• 25 Jernigan JA, Farr BM. Short-course therapy of catheter-related Staphylococcus aureus bacteremia: a meta-analysis. Ann Intern Med 1993; 119: 304-311
• 26 Chong YP, Moon SM, Bang KM. et al Treatment duration for uncomplicated Staphylococcus aureus bacteremia to prevent relapse: analysis of a prospective observational cohort study. Antimicrob Agents Chemother 2013; 57: 1150-1156
• 27 Gemmell CG, Edwards DI, Fraise AP. et al Guidelines for the prophylaxis and treatment of methicillin-resistant Staphylococcus aureus (MRSA) infections in the UK. J Antimicrob Chemother 2006; 57: 589-608
• 28 Mermel LA, Allon M, Bouza E, Craven DE. et al Clinical practice guidelines for the diagnosis and management of intravascular catheter-related infection: 2009 Update by the Infectious Diseases Society of America. Clin Infect Dis 2009; 49: 1-45
• 29 Kaasch AJ, Fatkenheuer G, Prinz-Langenohl R. et al Early oral switch therapy in low-risk Staphylococcus aureus bloodstream infection (SABATO): study protocol for a randomized controlled trial. Trials 2015; 16: 450
• 30 Iversen K, Ihlemann N, Gill SU. et al Partial Oral versus Intravenous Antibiotic Treatment of Endocarditis. N Engl J Med 2019; 380: 415-424
• 31 Willekens R, Puig-Asensio M, Ruiz-Camps I. et al Early oral switch to linezolid for low-risk patients with Staphylococcus aureus bloodstream infections: a propensity-matched cohort study. Clin Infect Dis 2018
• 32 Gath J, Charles B, Sampson J, Smithurst B. Pharmacokinetics and bioavailability of flucloxacillin in elderly hospitalized patients. J Clin Pharmacol 1995; 35: 31-36
• 33 Braun P, Tillotson JR, Wilcox C, Finland M. Cephalexin and cephaloglycin activity in vitro and absorption and urinary excretion of single oral doses in normal young adults. Appl Microbiol 1968; 16: 1684-1694
• 34 Chambers J, Sandoe J, Ray S. et al The infective endocarditis team: recommendations from an international working group. Heart 2014; 100: 524-527
• 35 Divisi D, Di Tommaso S, Di Leonardo G. et al 18-fluorine fluorodeoxyglucose positron emission tomography with computerized tomography versus computerized tomography alone for the management of solitary lung nodules with diameters inferior to 1.5 cm. Thorac Cardiovasc Surg 2010; 58: 422-426
• 36 Brondserud MB, Pedersen C, Rosenvinge FS. et al Clinical value of FDG-PET/CT in bacteremia of unknown origin with catalase-negative gram-positive cocci or Staphylococcus aureus. Eur J Nucl Med Mol Imaging 2019; 46: 1351-1358
• 37 Berrevoets MAH, Kouijzer IJE, Aarntzen E. et al (18)F-FDG PET/CT Optimizes Treatment in Staphylococcus Aureus Bacteremia and Is Associated with Reduced Mortality. J Nucl Med 2017; 58: 1504-1510
• 38 Ulmer M. GOÄ-Ratgeber: Abrechnung von kombinierten PET-/CT-Untersuchungen. Dtsch Arztebl International 2018; 115: A-2140
• 39 Tseng JR, Chen KY, Lee MH. et al Potential usefulness of FDG PET/CT in patients with sepsis of unknown origin. PLoS One 2013; 8: e66132
• 40 Hagel S, Weis S, Pletz MW. SOP Management der Staphylococcus-aureus-Blutstrominfektion. Intensivmedizin up2date 2018; 14: 361-366
• 41 Tubiana S, Duval X, Alla F. et al The VIRSTA score, a prediction score to estimate risk of infective endocarditis and determine priority for echocardiography in patients with Staphylococcus aureus bacteremia. J Infect 2016; 72: 544-553
• 42 Rybak MJ, Lomaestro BM, Rotschafer JC. et al Vancomycin therapeutic guidelines: a summary of consensus recommendations from the infectious diseases Society of America, the American Society of Health-System Pharmacists, and the Society of Infectious Diseases Pharmacists. Clin Infect Dis 2009; 49: 325-327